GlassScriptPhysician profile
Rizwan Tariq
NPI 1174836191
$1,687.18
in general payments reported to CMS, 2019-2025
35 companies · $143 in 2025
The $143 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $959 · 2020: $266 · 2022: $193 · 2024: $125 · 2025: $143.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $268.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $268.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $166.39 | 2019-2025 | Carvykti |
| Astellas Pharma US INC | $159.88 | 2019-2024 | Xospata |
| Astrazeneca Pharmaceuticals LP | $150.87 | 2019-2022 | |
| Genzyme Corporation | $130.47 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $129.57 | 2019-2020 | |
| Amgen INC. | $116.44 | 2019-2020 | |
| Genentech USA, INC. | $91.39 | 2019-2020 | |
| Eisai INC. | $51.21 | 2019 | |
| Incyte Corporation | $49.65 | 2019 | |
| Pfizer INC. | $46.20 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $41.08 | 2022 | |
| Exelixis INC. | $39.99 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $35.10 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $34.87 | 2019 | |
| Pharmacyclics LLC, An Abbvie Company | $34.48 | 2019-2020 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Taiho Oncology, INC. | $30.99 | 2019 | |
| Beigene USA, INC. | $27.14 | 2022 | |
| Verastem, INC. | $26.99 | 2019 | |
| Gilead Sciences, INC. | $26.70 | 2019 | |
| Alexion Pharmaceuticals, INC. | $26.60 | 2019 | |
| Merck Sharp & Dohme LLC | $25.78 | 2019 | |
| Amag Pharmaceuticals, INC. | $25.30 | 2019 | |
| Celgene Corporation | $22.77 | 2019 | |
| Tempus Ai, INC | $21.78 | 2025 | Xt Cdx |
| Seagen INC. | $21.36 | 2019 | |
| Foundation Medicine, INC. | $17.91 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.48 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $17.43 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.82 | 2020 | |
| Kite Pharma, INC. | $16.52 | 2020 | |
| Abbvie INC. | $14.96 | 2019 | |
| Lilly USA, LLC | $14.05 | 2020 | |
| Puma Biotechnology, INC. | $14.04 | 2019 | |
| Rigel Pharmaceuticals, INC. | $12.80 | 2019 | |
| Eusa Pharma (US) LLC | $12.17 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rizwan Tariq listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.